Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. HORIBA, Ltd.
  6. News
  7. Summary
    6856   JP3853000002

HORIBA, LTD.

(6856)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

HORIBA : Sickle Cell Anemia - Clinical Cases of Yumizen H2500 Hematology Analyzers "Chase...

08/24/2021 | 11:24am EDT

The 3rd issue of 'Chase the Case' is about 'Sicle Cell Anemia'. Sickle cell anemia is an inherited genetic disease, that affects the structure of hemoglobin and which develops only in homozygosis. Patient use Hydroxyurea. In typical cases of Hydroxyurea using sickle cell anemia patients, MCV is elevated and MCHC is decreased. Download and subscribe ► Chase the Case page

What is 'Chase the Case'?
Each month, HORIBA Medical shares a selected hematology clinical case with you in the PDF presentation named 'Chase the Case'. Every clinical case introduced here is picked up from a real laboratory in the world. It will help in a variety of ways:

  • Understanding the pattern of the matrix given by Yumizen H2500 hematology analyzers for various pathological cases.
  • As a learning opportunity for biology students.
  • HORIBA Medical users can contribute to the 'Chase the Case' by submitting clinical cases they obtained.

Disclaimer

Horiba Ltd. published this content on 24 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 August 2021 15:23:02 UTC.


© Publicnow 2021
All news about HORIBA, LTD.
10/20HORIBA : Technical Reports "Readout" No.55 is published
PU
10/19HORIBA : Acute myeloid leukemia type monoblastic (AML-M5b) - Clinical Cases of Yumizen...
PU
10/15HORIBA : Posted the presentation material for "SMBC Nikko Japan Series ESG Conference...
PU
10/15HORIBA : Posted the presentation material for "SMBC Nikko Japan Series ESG Conference Lond..
PU
10/14HORIBA : Veterinary haematology CPD webinar hosted by HORIBA to offer valuable best...
PU
10/06HORIBA : Development of the Partica CENTRIFUGE CN-300, Centrifugal Nanoparticle Analyzer ...
PU
10/04HORIBA : Scientific Validates the HORIBA Aqualog® Performance for Pharmaceutical...
PU
09/28VELODYNE LIDAR : Intelligent Traffic Monitoring Solution Chosen for Deployment at the Univ..
MT
09/28HORIBA : Sepsis and COVID - Clinical Cases of Yumizen H2500 Hematology Analyzers "Chase...
PU
09/16HORIBA : Scientific Partners with Covalent Metrology to Offer Glow Discharge...
PU
More news
Financials
Sales 2021 219 B 1 917 M 1 917 M
Net income 2021 20 269 M 178 M 178 M
Net cash 2021 37 969 M 333 M 333 M
P/E ratio 2021 15,7x
Yield 2021 1,79%
Capitalization 318 B 2 793 M 2 787 M
EV / Sales 2021 1,28x
EV / Sales 2022 1,21x
Nbr of Employees 8 269
Free-Float 91,6%
Chart HORIBA, LTD.
Duration : Period :
HORIBA, Ltd. Technical Analysis Chart | 6856 | JP3853000002 | MarketScreener
Technical analysis trends HORIBA, LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 7 530,00 JPY
Average target price 8 337,50 JPY
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Atsushi Horiba Chairman & Group Chief Executive Officer
Masayuki Adachi President & Representative Director
Sunao Kikkawa General Manager-Finance & Control Division
Juichi Saito Vice Chairman & Group Chief Operating Officer
Masao Okawa Managing Director & General Manager-Administration
Sector and Competitors
1st jan.Capi. (M$)
HORIBA, LTD.24.46%2 793
SMC CORPORATION4.83%38 549
COGNEX CORPORATION5.60%14 981
SHIMADZU CORPORATION15.34%12 124
MKS INSTRUMENTS, INC.-3.22%8 074
RENISHAW PLC-19.44%4 668